Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8715923 | Journal of Investigative Dermatology | 2018 | 4 Pages |
Abstract
Pachyonychia congenita is an incurable and often debilitating genodermatosis. Topical application of the antioxidative response inducer sulforaphane, however, alleviates disease symptoms in a murine pachyonychia congenita model, forecasting clinical benefits. The Coulombe laboratory now reports sex-dependent differences in sulforaphane responsiveness of pachyonychia congenita mice, thereby dampening treatment expectations but also unveiling novel aspects of sex-specific oxidative stress reactivity in the epidermis.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Rudolf E. Leube, Nicole Schwarz,